Abstract
Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine, memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary control and intervention for both diseases.
Keywords: Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Current Pharmaceutical Design
Title:Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Volume: 22 Issue: 23
Author(s): Xuan Thi-Anh Nguyen and Ly Le
Affiliation:
Keywords: Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Abstract: Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine, memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary control and intervention for both diseases.
Export Options
About this article
Cite this article as:
Thi-Anh Nguyen Xuan and Le Ly, Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders, Current Pharmaceutical Design 2016; 22 (23) . https://dx.doi.org/10.2174/1381612822666160420141325
DOI https://dx.doi.org/10.2174/1381612822666160420141325 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Research on Opioid Receptor Function
Current Drug Targets Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry Episodic Memory Impairment in Frontotemporal Dementia; A <sup>99m</sup>Tc- HMPAO SPECT Study
Current Alzheimer Research New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Regenerative Potential of Stem Cells Derived from Human Exfoliated Deciduous (SHED) Teeth during Engineering of Human Body Tissues
Current Stem Cell Research & Therapy Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Structure Diversity, Synthesis, and Biological Activity of Cyathane Diterpenoids in Higher Fungi
Current Medicinal Chemistry Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Treating Neurodegenerative Conditions Through the Understanding of Neuronal Apoptosis
Current Drug Targets - CNS & Neurological Disorders Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets